2000-2016年东南亚区域风疹及先天性风疹综合征控制进展
2013年世界卫生组织东南亚区域委员会采纳2020年消除麻疹并控制风疹及先天性风疹综合征的目标。本报告总结2000-2016年进展:含风疹疫苗第一剂覆盖率从2000年出生队列的3%升至2016年的15%,因六国引入该疫苗;
要点
- 含风疹疫苗第一剂覆盖率从2000年出生队列的3%升至2016年15%,因六国引入。
核心结论
- 实现东南亚区域风疹及先天性风疹综合征控制需持续投资提高常规含风疹疫苗覆盖率、定期开展高质量补充免疫活动以填补免疫空白并加强风疹及先天性风疹综合征监测。
研究设计与样本
- 本报告总结2000-2016年世界卫生组织东南亚区域风疹及先天性风疹综合征控制进展,基于估计含风疹疫苗第一剂覆盖率、补充免疫活动接种人数及报告风疹发病率。
主要发现
- 估计含风疹疫苗第一剂覆盖率从2000年出生队列的3%升至2016年的15%,因六国引入该疫苗。
- 孟加拉国、马尔代夫、斯里兰卡和泰国自2010年以来报告发病率降幅≥95%。
- 印度和印度尼西亚自2017年起分阶段引入含风疹疫苗,两国占东南亚区域出生队列的83%,预计含风疹疫苗第一剂覆盖率将快速上升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2013, the 66th session of the Regional Committee of the World Health Organization (WHO) South-East Asia Region (SEAR)* adopted the goal of elimination of measles and control† of rubella and congenital rubella syndrome (CRS) by 2020 (1). Rubella is the leading vaccine-preventable cause of birth defects. Although rubella typically causes a mild fever and rash in children and adults, rubella virus infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, or a constellation of congenital malformations known as CRS, commonly including visual, auditory, and/or cardiac defects, and developmental delay (2). Rubella and CRS control capitalizes on the momentum created by pursuing measles elimination because the efforts are programmatically linked. Rubella-containing vaccine (RCV) is administered as a combined measles and rubella vaccine, and rubella cases are detected through case-based surveillance for measles or fever and rash illness (3). This report summarizes progress toward rubella and CRS control in SEAR during 2000-2016. Estimated coverage with a first RCV dose (RCV1) increased from 3% of the birth cohort in 2000 to 15% in 2016 because of RCV introduction in six countries. RCV1 coverage is expected to increase rapidly with the phased introduction of RCV in India and Indonesia beginning in 2017; these countries are home to 83% of the SEAR birth cohort. During 2000-2016, approximately 83 million persons were vaccinated through 13 supplemental immunization activities (SIAs) conducted in eight countries. During 2010-2016, reported rubella incidence decreased by 37%, from 8.6 to 5.4 cases per 1 million population, and four countries (Bangladesh, Maldives, Sri Lanka, and Thailand) reported a decrease in incidence of ≥95% since 2010. To achieve rubella and CRS control in SEAR, sustained investment to increase routine RCV coverage, periodic high-quality SIAs to close immunity gaps, and strengthened rubella and CRS surveillance are needed.
引用
- Khanal S, Bahl S, Sharifuzzaman M, et al. Progress Toward Rubella and Congenital Rubella Syndrome Control - South-East Asia Region, 2000-2016. MMWR Morb Mortal Wkly Rep. 2018. PMID: 29851943. doi:10.15585/mmwr.mm6721a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。